Pathfinder
Risk Management Platform

POM

Pomalidomide Prescription Authorisation Form (PAF)

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.

Healthcare professionals are asked to report any suspected adverse drug reactions (ADRs) via the Yellow Card Scheme awww.mhra.gov.uk/yellowcard or by searching for MHRA Yellow Card in the Google Play or Apple App Store. Adverse reactions should also be r reported to the Pharmacare Group on **Tel: 0330 043 09089** or Email: **support@pharmacaregroup.co.uk**

A newly completed copy of this form MUST accompany EVERY Pomalidomide prescription for ALL patients in accordance with the Pomalidomide Pregnancy Prevention Programme (PPP), mandated by the Medicines and Healthcare products Regulatory Agency (MHRA). Email all completed Prescription Authorisation Forms to support@pharmacaregroup.co.uk immediately after dispensing.

TO BE COMPLETED BY PRESCRIBING HEALTHCARE PROFESSIONAL

1. Prescriber Contact Details

Full Name of Prescriber	First Name:	Surname:
Supervising Physician	First Name:	Surname:
Full Name of Prescribing Institution:		Postcode:
Prescriber Telephone/ Bleep Number:		

2. Please Verify if this PAF is for an initial or subsequent prescription of Pomalidomide – only tick one box

☐ Initial Prescription (full teratogenic risk counselling) ☐ Subsequent prescription (reminder teratogenic risk)

3. Patient Initials (First/Middle/Last)		**4. Patient Date of Birth (DD/MM/YYYY)**	
5. Prescriptions Date (DD/MM/YYYY			

6. Number of supply weeks:

☐ 4 weeks ☐ 8 weeks ☐ 12 weeks ☐ Other please enter number of weeks

Capsule Strength Prescribed (Tick)	1mg	2mg	3mg	4mg	**Total capsules supplied:**	
Number of Capsules per 4-week supply:						

7. Indication:

☐ Licensed
☐ Unlicensed – Specify indication below:

8. Patient Risk Category:

☐ Woman of Childbearing Potential (WCBP) (Please proceed to section 9, 10a & 11)
☐ Male (Please proceed to section 10b & 11)
☐ Woman of Non-Childbearing Potential (WNCBP) (Please proceed to section 11)

9. WCBP Pregnancy Test Date* (DD/MM/YYYY)	DD	MMM	YYYY

Pregnancy Test Result:*

☐ Negative ☐ Positive* ☐ Inconclusive* ☐ Test not done* Please provide reason

DO NOT prescribe if positive, inconclusive, test not done (except for repeat prescription in the case of confirmed tubal sterilisation) or pregnancy test date is more than 3 days before prescription date.

10. Patient Counselling: Only tick box(es) for applicable patient risk category

10a. WCBP

☐ The WCBP has been initially counselled and reminded about the expected teratogenic risk of Pomalidomide and the need to avoid pregnancy.

☐ The WCBP has been on at least one effective method of contraception for at least 4 weeks (includes male partners who have had a vasectomy, which must be confirmed by two negative semen tests; as well as absolute and continuous abstinence from heterosexual intercourse confirmed on a monthly basis).

10b. Male

☐ The male patient has been initially counselled and reminded about the expected teratogenic risk of Pomalidomide and understands the need to use a condom, if involved in sexual activity with a pregnant woman or a WCBP not using effective contraception (even if the male patient has had a vasectomy).

11. Prescriber's Declaration: As the Prescriber, I have read and understood the Additional Risk Minimisation Materials . I confirm the information provided on this PAF is accurate, complete and in accordance with the requirements of the PPP for Pomalidomide. I confirm treatment has been initiated and is monitored under the supervision of a physician experienced in managing immunomodulatory drugs

11a. Prescriber Signature	**11b. Signature Date (DD/MM/YYYY)**	DD	MM	YYYY

APPROVAL TO BE COMPLETED BY PHARMACIST

12. Pharmacy Contact Details:

Full Name of Pharmacist	First Name:	Surname:
Full Name of Pharmacy:		Postcode:

13. Name and postcode of Third-party Dispensing Pharmacy/ Home Delivery (Please complete only if applicable)

Name: Postcode:

Name:	
14. Dispensing Date (DD/MM/YYYY) DD MM YYYY	**15. Pharmacist Confirmation** Information which was not completed by the Prescriber and is required to fulfil the PPP for Pomalidomide has been received by the Pharmacist via other routes, or verbally confirmed by the Prescriber and / or patient and

Date of preparation of text: February 2024
Approved by MHRA: April 2024
PATH-POM-011_v.2.0

DO NOT dispense if pregnancy test is positive, inconclusive, test not done (except for repeat prescription in the case of confirmed tubal sterilisation), or as follows: For WCBP, do not dispense Pomalidomide unless negative pregnancy test was conducted within 3 days of the prescription date and dispensing is taking place within 7 days of the prescription date. No more than a 4-week supply to a WCBP and a 12-week supply to a male patient or a WNCBP should be dispensed.	documented in this form. Note: To indicate any changes / corrections made in the PAF, please add your initials and date against the changes and tick yes. ☐ **Yes** ☐ **Not Applicable**
16. Pharmacist's Declaration: As the Pharmacist, I have read and understood the Additional Risk Minimisation Materials. I confirm the information provided on this PAF is accurate, complete and in accordance with the requirements of the PPP for Pomalidomide.	
16a. Pharmacist Signature:	**16b. Signature Date (DD/MM/YYYY)** DD MM YYYY

A Guide to Completing the Prescription Authorisation Form (PAF)

This guide will help you to complete the Pomalidomide Prescription Authorisation Form (PAF). This form is available to prescribers and pharmacists in case of Pathfinder system unavailability. A PAF must be completed each time you prescribe Pomalidomide for all patients.

Instructions for prescribers

1.Print your name clearly.
Print the name of the Supervising Physician (if you are a non- physician prescriber), i.e. the physician experienced in managing immunomodulatory drugs and supervising treatment.
Print the full name of the Prescribing Institution, specifically the hospital name, where the patient is being treated.
2.Print your telephone number/bleep number.
Tick the appropriate box specifying whether this is an initial or subsequent prescription.
3.Enter the patient's initials.
4.Enter the patient's date of birth.
5.This refers to the date the prescription is authorised by the prescriber and not the date the patient is due to start treatment.
6.Please specify the total supply prescribed for this prescription. 4 weeks would equate to a 4-week cycle.
7.Please specify whether Pomalidomide is being used to treat a licensed or an unlicensed indication. If unlicensed, please specify the indication in the form.
8.Please specify whether the patient is a woman of childbearing potential, male or woman of non-childbearing potential.
9.For women of childbearing potential you must provide a valid negative pregnancy test date (within 3 days prior to prescription date). If this is not the case Pomalidomide must not be dispensed.

10.Complete this section appropriately to indicate that counselling and appropriate use of contraception has occurred. This is a requirement of the Pregnancy Prevention Programme.
11.You must sign, date and print your name to declare that the information provided on the form is accurate, complete and in accordance with the requirements of the Pregnancy Prevention Programme.

Instructions for pharmacists

12.Enter your full name and the full name and postcode of the pharmacy.
13.If applicable, complete the Third-Party Dispensing Pharmacy / Home Delivery information.
14.Please specify the date Pomalidomide was dispensed. This refers to the date the medication was given to the patient. Prior to dispensing, please check that all relevant sections of the form have been fully completed by the prescriber.
a.Counselling and contraception measures must be in place
b.Prescription must be accompanied by an accurately completed PAF
c.For women of childbearing potential Pomalidomide can only be dispensed within 7 days of the prescription date
d.Only a maximum of 4 weeks supply for women of childbearing potential, or a maximum of 12 weeks supply for all other patients, of Pomalidomide can be dispensed at any one time.
15.Please specify whether there were any changes made to the PAF. To indicate any changes / corrections made in the PAF, please add your initials and date against the changes and indicate yes in pharmacist confirmation.

16.You must sign, date and print your name to declare that the information provided on this form is accurate, complete and in accordance with the Pregnancy Prevention Programme. E- mail all completed Prescription Authorisation to **support@pharmacaregroup.co.uk** immediately after dispensing.



Further information is available from Pharmacare Group Pathfinder Pregnancy Prevention Programme:
Tel :0330 043 09089
Email: support@pharmacaregroup.co.uk

Electronic copies are also available on the Great Britain (GB) and Northern Ireland (NI) electronic medicines compendium websites: www.medicines.org.uk/emc (for Great Britain) or www.emcmedicines.com/en-GB/northernireland (for Northern Ireland).

Date of preparation of text: February 2024
Approved by MHRA: April 2024
PATH-POM-011_v.2.0